| Literature DB >> 26266415 |
Jacquie L Harper1, Iman M Khalil2, Lisa Shaw3, Marie-Lise Bourguet-Kondracki4, Joëlle Dubois5, Alexis Valentin6, David Barker7, Brent R Copp8.
Abstract
In an effort to more accurately define the mechanism of cell death and to establish structure-activity relationship requirements for the marine meroterpenoid alkaloids thiaplidiaquinones A and B, we have evaluated not only the natural products but also dioxothiazine regioisomers and two precursor quinones in a range of bioassays. While the natural products were found to be weak inducers of ROS in Jurkat cells, the dioxothiazine regioisomer of thiaplidiaquinone A and a synthetic precursor to thiaplidiaquinone B were found to be moderately potent inducers. Intriguingly, and in contrast to previous reports, the mechanism of Jurkat cell death (necrosis vs. apoptosis) was found to be dependent upon the positioning of one of the geranyl sidechains in the compounds with thiaplidiaquinone A and its dioxothiazine regioisomer causing death dominantly by necrosis, while thiaplidiaquinone B and its dioxothiazine isomer caused cell death via apoptosis. The dioxothiazine regioisomer of thiaplidiaquinone A exhibited more potent in vitro antiproliferative activity against human tumor cells, with NCI sub-panel selectivity towards melanoma cell lines. The non-natural dioxothiazine regioisomers were also more active in antiplasmodial and anti-farnesyltransferase assays than their natural product counterparts. The results highlight the important role that natural product total synthesis can play in not only helping understand the structural basis of biological activity of natural products, but also the discovery of new bioactive scaffolds.Entities:
Keywords: Aplidium; Jurkat; apoptosis; ascidian; cytotoxicity; farnesyltransferase; malaria; thiaplidiaquinone; thiazinoquinone
Mesh:
Substances:
Year: 2015 PMID: 26266415 PMCID: PMC4557015 DOI: 10.3390/md13085102
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of natural products thiaplidiaquinone A (1) and thiaplidiaquinone B (2).
Figure 2Structures of thiazine regioisomers 3 and 4 and precursor quinones 5 and 6.
Figure 3Comparison of DHR fluorescence by Jurkat cells treated with 1–6.
Figure 4Summary plots of flow cytometry data using Annexin V-FITC and PI to determine mode of cell death for 1–6 (necrotic PI+/AnV−; apoptotic PI−/AnV+; dead/late apoptosis PI+/AnV−).
In vitro antimalarial and anti-farnesyltransferase activity of compounds 1–6.
| Compound | FTase ( | FTase (H) c | |
|---|---|---|---|
| >17 d | 0.74 ± 0.20 | 0.78 ± 0.17 | |
| >17 d | 3.04 ± 0.30 | 1.22± 0.068 | |
| 4.56 ± 0.76 d | 0.22 ± 0.034 | 0.14 ± 0.0017 | |
| 4.39 ± 0.77 d | 0.098 ± 0.008 | 0.054 ± 0.005 | |
| 2.2 e | 3.90 ± 0.60 | 3.70 ± 0.60 | |
| 2.3 e | 6.16 ± 1.40 | 1.64 ± 0.30 | |
| Chloroquine f | 0.45 d, 0.0063 e | ||
| FTI 276 f | 0.010 ± 0.002 | 0.015 ± 0.004 |
IC50 values (μM) are reported as the average of three assays with an associated deviation, except for Pf data for 5 and 6 which is reported as the average of two independent assays; a Plasmodium falciparum; Trypanosoma brucei farnesyltransferase; Human farnesyltransferase; d Plasmodium falciparum, FcM29-Cameroon strain (chloroquine-resistant); e Plasmodium falciparum, NF54 strain (chloroquine sensitive), IEF stage; f Chloroquine and FTI 276 were used as positive controls.